AnGes Inc represents values of innovation, integrity, and commitment to improving human health. The company's corporate philosophy revolves around pioneering advanced technologies and providing cutting-edge solutions for medical needs. AnGes is dedicated to developing and commercializing innovative gene therapy products that address significant unmet medical needs. With their in-depth expertise and research-driven approach, AnGes strives to create breakthrough therapies that positively impact patient lives. By consistently pushing the boundaries of science and focusing on high-quality development processes, AnGes Inc aims to revolutionize the healthcare industry, making a profound difference in the treatment of various diseases.

AnGes Inc is primarily present in Japan and other Asian countries such as China and South Korea. With its headquarters in Osaka, Japan, AnGes Inc has established a strong presence in the pharmaceutical industry within the region. This Japanese company specializes in the research and development of innovative gene therapy products and has expanded its operations to include clinical trials and collaborations with various medical institutions. AnGes Inc's focus on these countries and regions reflects its commitment to advancing healthcare solutions and improving patient outcomes in Asia and beyond.

AnGes Inc has achieved significant milestones throughout the years. Notably, the company successfully developed and obtained approval for the world's first gene therapy product, HGF plasmid, for critical limb ischemia. Additionally, AnGes Inc achieved remarkable results in clinical trials for its novel COVID-19 DNA vaccine, which showcased promising immunogenicity and safety profiles. Moreover, the company has consistently focused on advancements in DNA medicine technology, further expanding its portfolio with innovative therapeutic candidates. With their groundbreaking research and pioneering gene therapy products, AnGes Inc continues to lead the way in the field of biotechnology and revolutionize the treatment landscape.

AnGes Inc. is a Japanese biopharmaceutical company that specializes in the development and commercialization of genetic medicines. Founded in 1999, the company has a rich history of research and innovation in the field of DNA-based therapies. AnGes Inc. has been actively involved in the development of innovative gene therapies for treating various diseases, including cardiovascular disorders and muscular dystrophy. With its cutting-edge technology and expertise, the company has established itself as a leading player in the genetic medicine industry. AnGes Inc. continues to strive for advancements in medical science through its dedication to research and development, aiming to improve the quality of life for patients worldwide.

The main competitors of AnGes Inc in the market include companies such as Novartis AG, Pfizer Inc, Moderna Inc, BioNTech SE, and Johnson & Johnson.

AnGes Inc primarily operates in the pharmaceutical and biotechnology industries.

The business model of AnGes Inc revolves around biotechnology and pharmaceutical research. AnGes focuses on developing innovative therapeutic solutions for various diseases, including cardiovascular, ophthalmic, and infectious diseases. The company specializes in gene therapy and has a strong emphasis on utilizing its proprietary technology called "Non-viral Gene Transfer" to deliver therapeutic genes to target cells in the human body. By harnessing the potential of gene therapy, AnGes aims to provide effective treatments that can significantly improve patients' quality of life. AnGes Inc continues to invest in research and development to advance its product pipeline and further contribute to the healthcare industry.

KGV-d ei saa praegu AnGes jaoks arvutada.

KUV-d ei ole võimalik hetkel AnGes jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele AnGes on 5/10.

Praegu ei saa AnGes käivet arvutada.

Praegu ei ole võimalik kasumit AnGes jaoks arvutada.

AnGes Inc is an innovative Japanese biotechnology company specializing in the development of new therapies for serious diseases. The company was founded in 1999 and is headquartered in Osaka, Japan. AnGes is known for its groundbreaking approaches to the development of gene therapies based on DNA plasmids to treat genetic diseases. AnGes has divided itself into three main business areas, namely Therapeutics, Diagnostics, and Research, to provide a comprehensive range of products. In the Therapeutics area, they focus on the development and marketing of gene therapies for the treatment of cardiovascular diseases, eye diseases, and cancer. Here, AnGes has developed its flagship product called Collategene, which is used to treat peripheral artery occlusive disease (PAOD). Collategene is a gene therapy that continuously promotes the formation of new blood vessels, contributing to the restoration of blood supply. In the Diagnostics area, AnGes offers a wide range of test kits and analysis tools to support diagnoses for various diseases. These include tests for markers of infectious diseases such as dengue and Zika viruses, as well as tests for cancer diagnosis. Through collaboration with leading in vitro diagnostics manufacturers and laboratories, AnGes supports the development of new and improved diagnostic tests. In the Research area, AnGes offers support and consultation for the development of gene therapies and drugs for customers from various industries. AnGes provides customized solutions for a wide range of applications, from the pharmaceutical industry to agriculture and biotech companies. Here, AnGes utilizes its proprietary DNA technology for the development of new drugs and promotes collaboration between industry and academic institutions. AnGes' business model is based on its promising gene therapy technology, which allows for targeted injection of DNA plasmids into damaged tissue, promoting the formation of new blood vessels and the regeneration of damaged tissue. This can provide compelling benefits for patients suffering from serious diseases such as PAOD and cancer. AnGes has established partnerships with leading pharmaceutical and biotech companies such as Mitsubishi Chemical, Sumitomo Chemical, and Shionogi to support the development and marketing of its products. These partnerships strengthen AnGes' product offering and expand its geographical portfolio in Asian and European markets. In summary, AnGes Inc is a company specialized in gene therapy that offers a comprehensive range of products for the treatment of various diseases. The company is on a growth trajectory and aims to improve the health and well-being of patients worldwide by providing innovative therapies. Through its dedicated research activities and collaboration with industry and academic institutions, AnGes strives to expand its expertise in gene therapy and develop new and improved solutions for patients.

AnGes maksab dividendi 0 JPY, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu AnGes jaoks arvutada või ettevõte ei maksa dividende välja.

AnGes ISIN on JP3127700007.

AnGes WKN on 779518.

AnGes tähis on 4563.T.

Viimase 12 kuu jooksul maksis AnGes dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab AnGes tõenäoliselt dividendi summas 0 JPY.

AnGes praegune dividenditootlus on .

AnGes maksab kvartaalset dividendi. See makstakse välja kuudel .

AnGes maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 JPY. See vastab dividenditootlusele 0 %.

AnGes on liigitatud sektorisse 'Tervis'.

Viimase AnGes dividendide saamiseks 15.7.2024 suuruses 0 JPY pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 15.7.2024.

Viimane dividendimakse toimus 15.7.2024.

Aastal 2023 maksis AnGes 0 JPY dividende.

AnGes dividendid makstakse välja JPY.